Marty N, Saeng-Aroon S, Heger E, Thielen A, Obermeier M, Pfeifer N, Kaiser R, Klimkait T. Adapting the geno2pheno[coreceptor] tool to HIV-1 subtype CRF01_AE by phenotypic validation using clinical isolates from South-East Asia. J Clin Virol. 2021 Feb 9;136:104755. doi: 10.1016/j.jcv.2021.104755.PMID: 33639408

Brown JA, Amstutz A, Nsakala BL, Seeburg U, Vanobberghen F, Muhairwe J, Klimkait T, Daniel Labhardt N.J  Extensive drug resistance during low-level HIV viraemia while taking NNRTI-based ART supports lowering the viral load threshold for regimen switch in resource-limited settings: a pre-planned analysis from the SESOTHO trial. Antimicrob Chemother. 2021 Feb 18:dkab025. doi: 10.1093/jac/dkab025. PMID: 33599270

Wan C, Bachmann N, Mitov V, Blanquart F, Céspedes SP, Turk T, Neumann K, Beerenwinkel N, Bogojeska J, Fellay J, Roth V, Böni J, Perreau M, Klimkait T, Yerly S, Battegay M, Walti L, Calmy A, Vernazza P, Bernasconi E, Cavassini M, Metzner KJ, Günthard HF, Kouyos RD; Swiss HIV Cohort Study. Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART. Nat Commun. 2020 Nov 2;11(1):5542. doi: 10.1038/s41467-020-19198-7

Amstutz A, Lejone TI, Khesa L, Muhairwe J, Bresser M, Vanobberghen F, Kopo M, Kao M, Nsakala BL, Tlali K, Klimkait T, Battegay M, Labhardt ND, Glass TR. Home-based oral self-testing for absent and declining individuals during a door-to-door HIV testing campaign in rural Lesotho (HOSENG): a cluster-randomised trial. Lancet HIV. 2020 Nov;7(11):e752-e761. doi: 10.1016/S2352-3018(20)30233-2

Kouyos RD, Rusert P, Kadelka C, Marzel A, Ebner H, Schanz M, Liechti T, Friedrich N, Braun DL, Scherer A, Huber M, Weber J, Uhr T, Kuster H, Chave J-P, Cavassini M, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Günthard HF, Trkola A, and the Swiss HIV Cohort Study. Tracing HIV-1 strains that imprint broadly neutralising antibody responses. Nature 2018; 561(7723):406-410. doi: 10.1038/s41586-018-0517-0.